New vision for viral hepatitis treatment: the intersection of traditional therapy with emerging drugs
Summary: viral hepatitis is a major global public health problem and a serious threat to human health. This paper is intended to explore the current status of the use of traditional and emerging drugs in the area of viral hepatitis treatment and the new advances resulting from their convergence. By elaborating on traditional antivirus, hepatitis and other treatments, as well as on the new direct antiviral drugs that have emerged in recent years, they analyse their respective strengths and limitations and demonstrate how they can be combined in clinical practice to improve treatment outcomes and provide a more comprehensive approach and strategy for the treatment of viral hepatitis.
Introduction
Hepatitis viral is mainly hepatitis A, B, C, D and E, of which hepatitis B and C are the main causes of chronic hepatitis, cirrhosis and liver cancer. Over the years, traditional therapy has played an important role in the treatment of viral hepatitis, and as medical research continues, the emergence of emerging drugs offers new hope for the treatment of viral hepatitis. The combination of the two is gradually changing the treatment patterns for viral hepatitis.
II. The use of traditional therapies in viral hepatitis treatment
1. Anti-virus treatment
Interference is a drug that was used earlier for hepatitis B treatment. It has the dual role of anti-virus and immuno-regulation. Common interferosols are subject to multiple per-week subcutaneous injections, while long-acting interferostats prolong their duration and reduce the number of injections. It inhibits the replicability of the virus by activation of the intracellular antiviral protein gene, while enhancing the lethal effects of the organism immunocells on the infected cells of the hepatitis B virus. However, there are more adverse reactions to disrupters, such as influenza sample symptoms, bone marrow inhibition, mental abnormalities, etc., and some patients have limited therapeutic effects and high post-treatment relapse rates.
• Nucleotide analogues such as Ramifdun, Adfwey, Nteikave, by inhibiting the retro-enzyme activity of the Hepatitis B virus and the extension of the virus’s DNA chain, thus inhibiting the replicability of the virus. Such drugs are easy to take oral and antiviral, and can rapidly reduce the levels of Hepatitis B virus DNA and improve hepatitis. However, long-term application can easily lead to viral resistance variability, such as the gradual increase in drug resistance after the Ramidic treatment 1-2 years, as well as a certain risk of drug resistance in Adfwey esters, which, although relatively low, still appears in a small number of patients after long-term treatment. 2. Hepatotherapy
Hepato-preventing drugs are commonly used in the form of lysic acid formulations, water falciparum, etc. The glyceric acid formulations are resistant to inflammation, protection of hepatocellular membrane and improvement of liver function. It can reduce the response to hepatitis by inhibiting the creation and release of inflammatory factors and reduce the level of muscular enzymes. Aqueousin, in turn, stabilizes the hepatic membrane, removes the free radicals and promotes the repair and regeneration of the hepatic cell. Hepatitis treatment has a role to play in improving the patient ‘ s liver function indicators and mitigating symptoms, but the hepatitis B virus cannot be eradicated from its roots.
(iii) Traditional treatment of hepatitis C
The traditional treatment of hepatitis C is mainly based on interference with the United Libavirin. As mentioned above, the interventionist mechanism, Libavirin, is a wide spectrum antiviral drug, which, in combination with the interferenceor, can enhance the antiviral effect. However, there are significant deficiencies in this joint treatment programme, and the adverse effects of jammers are equally disturbing for patients, and Libaverin can cause severe adverse effects such as soluble anaemia. Moreover, for patients with Hepatitis 1 type C, the rate of continuous virological response for traditional treatment is relatively low, at about 40 – 50 per cent.
III. Emerging drug breakthroughs in viral hepatitis treatment
1. New types of nucleic acid analogue
TAF is a precursor drug for Novovea, which has a higher liver target, has a strong antiviral effect at a lower dose, and is significantly less toxic to kidneys and bones than Novovea difuran. It is more effective in curbing the replicability of hepatitis B virus, improving the liver histology of patients, and having a very low resistance rate, providing better choices for hepatitis B patients, especially those with long-term treatment and risk of kidneys or bones. 2. Hepatitis B virus into inhibitor
• For example, Myrcrudex B, which prevents the virus from entering the liver cell by blocking the combination of the hepatitis B virus with a hepatocellular receptor. This mechanism of action, unlike traditional antivirals, works in the early stages of hepatitis B virus infection. Although still at the research stage, some antiviral potential has been demonstrated and is expected to be applied in conjunction with existing antivirals to improve treatment effectiveness.
(ii) Emerging drugs for hepatitis C
Direct antiviral drugs (DAAs) represent a major breakthrough in hepatitis C treatment. These drugs target key targets in the life cycle of the hepatitis C virus, such as NS3/4A protein enzyme, NS5A protein and NS5B polymerase. Different types of DAAs can be used in combination, such as Sophos-Buy U. Vipatwe, with high-efficiency, low-toxic and short-term treatment. Hepatitis C is treated in a way that changes the treatment model for hepatitis C, which gradually moves from an incurable disease to a curable one.
IV. Combining traditional therapies with emerging drugs
(i) Advantages of joint treatment programmes
In hepatitis B treatment, the use of traditional nucleic acid analogues, such as Nteikawe, in conjunction with the new drug TAF, can create synergies to inhibit the replicability of viruses while reducing the risk of drug resistance. Joint treatment may be an effective strategy for some incurable hepatitis B patients, such as those with viral variations or poor response to a single drug. In hepatitis C treatment, some special patients, such as those who combine severe hepatitis C cirrhosis, can be treated with appropriate traditional treatment, such as hepatitis protection, in conjunction with DAAs, in order to improve liver function, reduce hepatitis, improve patient tolerance and overall efficacy of treatment.
(ii) Examples of application in clinical practice
In clinical studies, for some hepatitis B cirrhosis patients, antiviral treatment in Ntecavay, control of viral reproduction, improvement of hepatitis disease, replacement of TAF for treatment after relatively stable conditions, further inhibition of the virus, reduction of the risk of long-term adverse reaction, continuous improvement of liver function indicators such as aminoase and chlamyrin, and improvement of liver fibrosis indicators. In the case of hepatitis C treatment, some patients who have a gene type 3 hepatitis C combination of light fatty livers have been treated with sophosphate, together with a water fascist hepatitis drug, and not only a good virology response but also a certain improvement in liver fatty variability and a marked improvement in the quality of life of patients.
Conclusions
The treatment of viral hepatitis continues to develop, driven by both traditional therapies and emerging drugs. Traditional therapy provides the foundation for viral hepatitis treatment, while emerging drugs offer new opportunities to improve treatment effectiveness and patient prognosis. The intersection of the two provides clinical practitioners with more treatment options and more flexible treatment strategies. In the future, as medical research deepens, it is expected that treatment will be further optimized, the cure of viral hepatitis will be increased, the incidence of complications such as cirrhosis and liver cancer will be reduced and, ultimately, the effective control and elimination of viral hepatitis will be achieved. At the same time, there is a need to strengthen research on emerging drugs, focusing on their long-term efficacy, adverse effects and drug cost-effectiveness, in order to better apply them in clinical practice for the benefit of a wide range of viral hepatitis patients.
Hepatitis